The Federal Circuit has provided some guidance on the issue of 180 days’ notice of launch in a recent biosimilars ruling, in Amgen v Apotex, but practitioners say there will be a lot more litigation before the patent dance is fully clarified
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
A ruling concerning a juicing machine, a tussle over a preliminary injunction and a new judge in Paris were among the top talking points this fortnight
The Iconix v Dream Pairs dispute, to be heard at the UK Supreme Court, concerns trademarks owned by sports brand Umbro and the issue of post-sale confusion